PT-141 (Bremelanotide)
An FDA-approved melanocortin agonist for hypoactive sexual desire, acting centrally on arousal pathways rather than vasculature.
Overview
PT-141, marketed as Vyleesi, is a synthetic analog of α-MSH derived from research on Melanotan II. Unlike traditional libido drugs, it acts centrally in the brain via melanocortin receptors involved in sexual arousal — making it effective in both men and women.
Benefits
- Approved for female hypoactive sexual desire disorder
- Central mechanism (not vasodilatory)
- Works without ongoing sexual stimulation
- Effective in both sexes
Mechanism of Action
Activates MC4R (with secondary MC1R/MC3R activity) in the central nervous system, modulating dopaminergic pathways involved in sexual arousal and motivation.
Dosage (informational only)
- Typical range
- 0.75–1.75 mg per dose
- Frequency
- As needed, typically 45 minutes before activity
Avoid in users with uncontrolled hypertension. Limit doses per 24-hour period.
Side Effects
- Nausea (most common)
- Flushing or headache
- Transient blood pressure elevation
- Possible facial pigmentation with chronic use
Related peptides
A short peptide derived from kisspeptin, the master regulator of the reproductive hormone axis.
The 'bonding hormone' used clinically in obstetrics and increasingly studied in research for its effects on social cognition and mood.
A long-acting GLP-1 receptor agonist studied for its effects on appetite, satiety, and glucose regulation.